Mark Chandy

Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration-approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cel...